Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19

OBJECTIVE: The novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic, but the factors influencing viral RNA shedding, which would help inform optimal control strategies, remain unclear

METHODS: The clinical course and viral RNA shedding pattern of 267 consecutive symptomatic COVID-19 patients admitted to the hospital from January 20, 2020 to March 15, 2020 were evaluated retrospectively

RESULTS: The median duration of viral RNA shedding was 12 days (interquartile range 8-16 days) after the onset of illness. Of the 267 patients included in this study, 65.2% had viral RNA clearance within 14 days, 88.8% within 21 days, and 94.4% within 28 days. Older age (hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.98-1.00; p = 0.04), time lag from illness onset to hospital admission (HR 0.91, 95% CI 0.88-0.94; p < 0.001), diarrhea (HR 0.59, 95% CI 0.36-0.96; p = 0.036), corticosteroid treatment (HR 0.60, 95% CI 0.39-0.94; p = 0.024), and lopinavir/ritonavir use (HR 0.70, 95% CI 0.52-0.94; p = 0.014) were significantly and independently associated with prolonged viral RNA shedding

CONCLUSIONS: Early detection and timely hospital admission may be warranted for symptomatic COVID-19 patients, especially for older patients and patients with diarrhea. Corticosteroid treatment is associated with prolonged viral RNA shedding and should be used with caution. Lopinavir/ritonavir use may be associated with prolonged viral RNA shedding in non-severe patients; further randomized controlled trials are needed to confirm this finding

Year of Publication: 2020
Contained in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases Vol. 98 (2020), p. 252-260
All journal articles: Search for all articles in this journal
Language: English
Contributors: Chen, Xudan | Author
Zhu, Baoyi
Hong, Wenxin
Zeng, Jianwen
He, Xi
Chen, Jingfeng
Zheng, Haipeng
Qiu, Shuang
Deng, Ying
Chan, Juliana C N
Wang, Jian
Zhang, Yuying
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 2494G1JF75
COVID-19
Corticosteroid
Diarrhea
Journal Article
Lopinavir/ritonavir
O3J8G9O825
Risk factors
Viral RNA shedding
Additional Keywords: *Virus Shedding
Adult
Aged
Betacoronavirus
Coronavirus Infections
Female
Hospitalization
Humans
Lopinavir
Male
Middle Aged
Pandemics
Pneumonia, Viral
RNA, Viral
Retrospective Studies
Ritonavir
ISSN: 1878-3511
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 21.09.2020
Date Revised 21.09.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32619760
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.ijid.2020.06.091
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 05109nma a2201021 c 4500
001 NLM312885148
003 DE-601
005 20200922213724.0
007 cr uuu---uuuuu
008 200704s2020 000 0 eng d
024 7 |a 10.1016/j.ijid.2020.06.091  |2 doi 
028 5 2 |a pubmed20n1347.xml 
035 |a S1201-9712(20)30526-9 
035 |a (DE-599)NLM32619760 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Chen, Xudan 
245 1 0 |a Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 21.09.2020 
500 |a Date Revised 21.09.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved. 
520 |a OBJECTIVE: The novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic, but the factors influencing viral RNA shedding, which would help inform optimal control strategies, remain unclear 
520 |a METHODS: The clinical course and viral RNA shedding pattern of 267 consecutive symptomatic COVID-19 patients admitted to the hospital from January 20, 2020 to March 15, 2020 were evaluated retrospectively 
520 |a RESULTS: The median duration of viral RNA shedding was 12 days (interquartile range 8-16 days) after the onset of illness. Of the 267 patients included in this study, 65.2% had viral RNA clearance within 14 days, 88.8% within 21 days, and 94.4% within 28 days. Older age (hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.98-1.00; p = 0.04), time lag from illness onset to hospital admission (HR 0.91, 95% CI 0.88-0.94; p < 0.001), diarrhea (HR 0.59, 95% CI 0.36-0.96; p = 0.036), corticosteroid treatment (HR 0.60, 95% CI 0.39-0.94; p = 0.024), and lopinavir/ritonavir use (HR 0.70, 95% CI 0.52-0.94; p = 0.014) were significantly and independently associated with prolonged viral RNA shedding 
520 |a CONCLUSIONS: Early detection and timely hospital admission may be warranted for symptomatic COVID-19 patients, especially for older patients and patients with diarrhea. Corticosteroid treatment is associated with prolonged viral RNA shedding and should be used with caution. Lopinavir/ritonavir use may be associated with prolonged viral RNA shedding in non-severe patients; further randomized controlled trials are needed to confirm this finding 
611 2 7 |a Journal Article  |2 gnd 
653 2 |a Adult  |6 D000328 
653 2 |a Aged  |6 D000368 
653 2 |a Betacoronavirus  |6 D000073640  |a *genetics  |6 Q000235  |a isolation & purification  |6 Q000302  |a physiology  |6 Q000502 
653 2 |a Coronavirus Infections  |6 D018352  |a diagnosis  |6 Q000175  |a drug therapy  |6 Q000188  |a *virology  |6 Q000821 
653 2 |a Female  |6 D005260 
653 2 |a Hospitalization  |6 D006760 
653 2 |a Humans  |6 D006801 
653 2 |a Lopinavir  |6 D061466  |a therapeutic use  |6 Q000627 
653 2 |a Male  |6 D008297 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a diagnosis  |6 Q000175  |a drug therapy  |6 Q000188  |a *virology  |6 Q000821 
653 2 |a RNA, Viral  |6 D012367  |a *genetics  |6 Q000235  |a metabolism  |6 Q000378 
653 2 |a Retrospective Studies  |6 D012189 
653 2 |a Ritonavir  |6 D019438  |a therapeutic use  |6 Q000627 
653 2 |a *Virus Shedding  |6 D017201  |a drug effects  |6 Q000187 
655 7 |a COVID-19  |2 gnd 
655 7 |a Corticosteroid  |2 gnd 
655 7 |a Diarrhea  |2 gnd 
655 7 |a Lopinavir/ritonavir  |2 gnd 
655 7 |a Risk factors  |2 gnd 
655 7 |a Viral RNA shedding  |2 gnd 
655 7 |a RNA, Viral  |2 gnd 
655 7 |a Lopinavir  |2 gnd 
655 7 |a 2494G1JF75  |2 gnd 
655 7 |a Ritonavir  |2 gnd 
655 7 |a O3J8G9O825  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a Corticosteroid 
689 1 2 |a Diarrhea 
689 1 3 |a Lopinavir/ritonavir 
689 1 4 |a Risk factors 
689 1 5 |a Viral RNA shedding 
689 1 |5 DE-601 
689 2 0 |a RNA, Viral 
689 2 1 |a Lopinavir 
689 2 2 |A r  |a 2494G1JF75 
689 2 3 |a Ritonavir 
689 2 4 |A r  |a O3J8G9O825 
689 2 |5 DE-601 
700 1 |a Zhu, Baoyi 
700 1 |a Hong, Wenxin 
700 1 |a Zeng, Jianwen 
700 1 |a He, Xi 
700 1 |a Chen, Jingfeng 
700 1 |a Zheng, Haipeng 
700 1 |a Qiu, Shuang 
700 1 |a Deng, Ying 
700 1 |a Chan, Juliana C N 
700 1 |a Wang, Jian 
700 1 |a Zhang, Yuying 
773 0 8 |i in  |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases  |g Vol. 98 (2020), p. 252-260  |q 98<252-260  |w (DE-601)NLM094733481  |x 1878-3511 
856 4 1 |u http://dx.doi.org/10.1016/j.ijid.2020.06.091  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 98  |j 2020  |b 24  |c 09  |h 252-260